科兴制药：拟变更募资用途、续聘审计机构并于25年12月31日开会审议

Group 1 - The company will hold its third extraordinary general meeting on December 31, 2025, to review two proposals [1] - The first proposal involves reallocating 109.15 million yuan of raised funds and 15.87 million yuan of income from the "Drug Production Base Expansion Project" to the "R&D Center Upgrade Project," increasing the total fundraising amount to 472.48 million yuan and extending the implementation period to December 31, 2028 [1] - The second proposal is to reappoint Crowe Horwath as the auditing firm for the 2025 fiscal year, with the audit fee remaining at 1.3 million yuan, consistent with 2024 [1]